Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
147 studies found for:    novel influenza a (h1n1)
Show Display Options
Rank Status Study
21 Completed
Has Results
H1N1 Vaccine in Pregnant Women
Condition: Influenza
Intervention: Biological: Inactivated H1N1 Vaccine
22 Recruiting Respiratory Virus Outpatient Study (FLU 002 Plus)
Condition: Influenza and Other Novel Respiratory Viruses
Intervention:
23 Recruiting Respiratory Virus Hospitalization Study (FLU 003 Plus)
Conditions: Influenza;   Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV);   Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Intervention:
24 Completed Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza
Conditions: H1N1 Influenza;   Seasonal Influenza
Intervention:
25 Completed
Has Results
Relenza® Sentinel Site Monitoring Program in Japan
Condition: Influenza, Human
Intervention: Drug: zanamivir
26 Unknown  Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients
Conditions: Serology Analysis;   Novel H1N1 Influenza Vaccination;   Pediatric Haemato-oncology Patients
Intervention: Biological: Influenza A (H1N1) 2009 monovalent vaccine, inactivated
27 Completed Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects
Condition: Swine-Origin Influenza A H1N1 Virus
Intervention: Biological: Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
28 Completed Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults
Condition: Influenza
Interventions: Biological: VAX128;   Biological: Placebo
29 Completed Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects
Condition: Influenza
Intervention: Biological: Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
30 Completed
Has Results
Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
Condition: Influenza
Intervention: Biological: Inactivated H1N1 vaccine
31 Unknown  The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A
Condition: H1N1 Influenza
Interventions: Drug: Vitamin (vitamin A 15 mg,C 500 mg, E 400IU);   Drug: Placebo (digestive tablet)
32 Completed
Has Results
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
Condition: Novel 2009 Influenza H1N1
Interventions: Biological: MF59-eH1N1_f;   Biological: eH1N1_f
33 Completed A Study to Validate a New Oral Fluid/Saliva Antibody Test for Novel H1N1v Influenza
Condition: H1N1 Virus
Intervention:
34 Completed Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10
Condition: Pandemic Influenza Disease
Intervention: Biological: Monovalent A/H1N1 influenza vaccine
35 Completed Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device
Condition: Influenza Infection
Intervention: Biological: S-OIV H1N1 vaccine
36 Completed Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
Condition: Pandemic Influenza
Intervention: Biological: Monovalent A/H1N1 influenza vaccine
37 Completed Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
Condition: Pandemic Influenza
Intervention: Biological: Monovalent A/H1N1 influenza vaccine
38 Completed Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age
Condition: Pandemic Influenza
Intervention: Biological: Monovalent A/H1N1 influenza vaccine
39 Completed Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age
Condition: Pandemic Influenza
Intervention: Biological: Monovalent A/H1N1 influenza vaccine
40 Completed Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors
Conditions: H1N1 Influenza Virus;   Invasive Solid Tumors
Interventions: Biological: adjuvanted A(H1N1) influenza vaccine;   Biological: non-adjuvanted A(H1N1) influenza vaccine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.